Collin Todd
Vermögen: - $ am 31.07.2026
Vermögen: - $ am 31.07.2026
Collin Todd is currently Director at CTRL Therapeutics, Inc. and Senior VP-Strategy & Business Development at Odyssey Therapeutics, Inc. Formerly, Mr. Todd was an Analyst at OrbiMed Advisors Private Equity from 2015 to 2016 and an Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. Education includes undergraduate studies at the University of California.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.05.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2024 |
CTRL Therapeutics, Inc.
CTRL Therapeutics, Inc. BiotechnologyHealth Technology Develops liquid biopsy platform that isolates circulating tumor cells from blood | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Private-Equity-Analyst | 01.11.2016 |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CTRL Therapeutics, Inc.
CTRL Therapeutics, Inc. BiotechnologyHealth Technology Develops liquid biopsy platform that isolates circulating tumor cells from blood | Health Technology |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen